Gideon Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Gideon Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-7,314	Closed	-$1.24M	–	393
2019 Q3	$1.24M	Buy	+7,314	New	+$1.29M	0.41%	92
2019 Q2	–	Sell	-2,529	Closed	-$465K	–	443
2019 Q1	$465K	Sell	2,529 -12	-0.5%	-$2.22K	0.17%	185
2018 Q4	$421K	Buy	+2,541	New	+$440K	0.17%	185
2018 Q3	–	Sell	-2,070	Closed	-$352K	–	503
2018 Q2	$352K	Sell	2,070 -1,216	-37%	-$188K	0.18%	221
2018 Q1	$536K	Buy	+3,286	New	+$537K	0.33%	106
2017 Q3	–	Sell	-1,755	Closed	-$226K	–	383
2017 Q2	$226K	Buy	+1,755	New	+$211K	0.25%	202
2015 Q3	–	Sell	-3,440	Closed	-$425K	–	333
2015 Q2	$425K	Buy	+3,440	New	+$433K	0.18%	156

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Gideon Capital Advisors's VRTX Position: Q4 2019 in Review

Gideon Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2019, closing a stake of 7,314 shares — an estimated $1.24M sold.

Gideon Capital Advisors first reported a position in VRTX in Q2 2015 and held it in 7 quarters. The position peaked at $1.24M in Q3 2019. 814 funds tracked by Wall St. Rank hold VRTX as of Q4 2019.

Gideon Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Gideon Capital Advisors sold 7,314 Vertex Pharmaceuticals shares in Q4 2019, an estimated $1.24M.
Gideon Capital Advisors first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 7 quarters.
Gideon Capital Advisors's Vertex Pharmaceuticals position peaked at $1.24M in Q3 2019.
814 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2019.

Based on Gideon Capital Advisors's 13F filing for Q4 2019, filed 11 Feb 2020.